Community Advisory Group Bulletin – DBN

A Phase 2 Open-Label Partially Randomized Trial to Evaluate the Efficacy, Safety and Tolerability of combinations of bedaquiline, moxifloxacin, PA-824 and pyrazinamide during 8 weeks of treatment in Adult Subjects with Newly Diagnosed Drug-Sensitive or Multi Drug-Resistant, Smear Positive Pulmonary Tuberculosis.

Download the full bulletin here


Leave a Reply

Your email address will not be published. Required fields are marked *